Magdalene89
2021-07-13
Good
You Should Know About Monday's 2 Big Nasdaq Winners<blockquote>你应该知道周一纳斯达克的两大赢家</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":142183539,"tweetId":"142183539","gmtCreate":1626136523021,"gmtModify":1633929816602,"author":{"id":3582660441215591,"idStr":"3582660441215591","authorId":3582660441215591,"authorIdStr":"3582660441215591","name":"Magdalene89","avatar":"https://static.tigerbbs.com/ebb4c866593af8c808394f620f5b7d43","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/142183539","repostId":1198299202,"repostType":4,"repost":{"id":"1198299202","kind":"news","pubTimestamp":1626136031,"share":"https://www.laohunote.com/m/news/1198299202?lang=zh_CN&edition=full","pubTime":"2021-07-13 08:27","market":"us","language":"en","title":"You Should Know About Monday's 2 Big Nasdaq Winners<blockquote>你应该知道周一纳斯达克的两大赢家</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198299202","media":"Motley Fool","summary":"One's a well-known name, while the other has plenty of potential.\n\nKey Points\n\nMarkets were generall","content":"<p> One's a well-known name, while the other has plenty of potential. <b>Key Points</b></p><p><blockquote>一个是家喻户晓的名字，而另一个有很大的潜力。<b>要点</b></blockquote></p><p> <ul> <li>Markets were generally higher on Monday.</li> <li>One stock rose on news about technological advances with its key products.</li> <li>Another stock released favorable study results in a clinical trial.</li> </ul> The Possible Demise of the iPhone</p><p><blockquote><ul><li>周一市场普遍走高。</li><li>一只股票因其关键产品技术进步的消息而上涨。</li><li>另一只股票在临床试验中发布了有利的研究结果。</li></ul>iPhone可能消亡</blockquote></p><p> Stocks were largely higher on Monday after overcoming a slow start to the trading week. By 2:30 p.m. EDT, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)had climbed about 0.2%, with aspirations to finish at an all-time high.</p><p><blockquote>在克服了交易周开局缓慢的局面后，周一股市大幅走高。到下午 2:30美国东部时间，<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）上涨约 0.2%，有望创下历史新高。</blockquote></p><p> A couple of stocks contributed significantly to the positive mood on Wall Street.<b>Tesla</b>(NASDAQ:TSLA)is a perennial favorite among many investors, and its stock was among the best performers in the mega-cap arena. Meanwhile, tiny<b>Celldex Therapeutics</b>(NASDAQ:CLDX)enjoyed much larger gains that stemmed from good news about one of its candidate treatments. Below, we'll go into more detail about today's moves.</p><p><blockquote>几只股票对华尔街的积极情绪做出了重大贡献。<b>特斯拉</b>（纳斯达克股票代码：TSLA）一直是许多投资者的最爱，其股票是大型股领域表现最好的股票之一。同时，小小的<b>Celldex 治疗</b>（纳斯达克股票代码：CLDX）由于其候选疗法之一的好消息而获得了更大的涨幅。下面，我们将更详细地介绍今天的走势。</blockquote></p><p> <b>Tesla gears up</b></p><p><blockquote><b>特斯拉加快步伐</b></blockquote></p><p> Shares of Tesla were higher by 4%. The stock overcame negative comments from one set of Wall Street analysts even as CEO Elon Musk gave testimony about Tesla's purchase of its SolarCity unit from several years back.</p><p><blockquote>特斯拉股价上涨 4%。尽管首席执行官埃隆·马斯克 (Elon Musk) 就特斯拉几年前收购其 SolarCity 部门一事作证，但该股克服了一组华尔街分析师的负面评论。</blockquote></p><p> One explanation for the optimism about the stock relates to Tesla's self-driving vehicle technology. The company started to enable vehicles whose owners paid in advance for incremental software updates toupgrade to the latest beta version of Tesla's autonomous driving software. Yet Tesla warned drivers not to assume too much about the driver assistance system, in an effort to avoid some of the accidents that have resulted from Tesla owners counting on their vehicles to do too much without any human intervention.</p><p><blockquote>对该股持乐观态度的一个解释与特斯拉的自动驾驶汽车技术有关。该公司开始让车主提前支付增量软件更新费用的车辆升级到特斯拉自动驾驶软件的最新测试版。然而，特斯拉警告司机不要对驾驶员辅助系统假设太多，以避免一些事故，这些事故是由于特斯拉车主在没有任何人工干预的情况下指望他们的车辆做得太多而导致的。</blockquote></p><p> Yet analysts at Citi were skeptical about the release, arguing that early indications suggest minimal improvement in features. Citi is among the most bearish analysts on Tesla, with a sell rating and a price target of $175 per share.</p><p><blockquote>然而，花旗分析师对此次发布持怀疑态度，认为早期迹象表明功能改进甚微。花旗是特斯拉最悲观的分析师之一，给予卖出评级，目标价为每股 175 美元。</blockquote></p><p> Meanwhile, many shareholders are watching Musk's testimony in Delaware court, in which he's been asked to defend his role in Tesla's SolarCity acquisition. Naysayers have centered on family relationships between top-level executives at both companies. Cross-examination, however, got heated and seemingly personal.</p><p><blockquote>与此同时，许多股东正在关注马斯克在特拉华州法院的证词，他被要求为自己在特斯拉收购 SolarCity 中的角色进行辩护。反对者集中在两家公司高层管理人员之间的家庭关系上。然而，交叉询问变得激烈，似乎是针对个人的。</blockquote></p><p> Tesla's ability to move higher shows that shareholders are able to separate Musk's role from the future success of the company. That's a positive development and could support future gains for theelectric car stock.</p><p><blockquote>特斯拉走高的能力表明，股东能够将马斯克的角色与公司未来的成功分开。这是一个积极的发展，可能会支持电动汽车股票未来的上涨。</blockquote></p><p> <b>Celldex gets a win</b></p><p><blockquote><b>Celldex 获胜</b></blockquote></p><p> Elsewhere, shares of Celldex Therapeutics moved higher by 23%. The little-known biotech got an early win with a key candidate treatment in its development pipeline.</p><p><blockquote>在其他地方，Celldex Therapeutics 的股价上涨了 23%。这家鲜为人知的生物技术公司凭借其开发管道中的关键候选疗法取得了早期胜利。</blockquote></p><p> Celldex released positive data late Fridayon its CDX-0159 candidate treatment, which aims to help patients who are dealing with chronic urticaria, another name for hives. The phase 1b study involved 19 patients, and all but one of them had a complete response that included depletion of skin mast cells.</p><p><blockquote>Celldex 周五晚些时候发布了其 CDX-0159 候选疗法的积极数据，该疗法旨在帮助患有慢性荨麻疹（荨麻疹的另一个名称）的患者。1b期研究涉及19名患者，除一名患者外，其余患者均有完全缓解，包括皮肤肥大细胞耗竭。</blockquote></p><p> Obviously, it's still early in the clinical trial process, but CEO Anthony Marucci was still optimistic about the results. The Celldex leader believes that the news points to a higher probability that CDX-0159 could help patients with other related diseases as well, and he's hopeful that the treatment's indications will expand over time.</p><p><blockquote>显然，目前还处于临床试验过程的早期阶段，但CEO安东尼·马鲁奇（Anthony Marucci）仍然对结果持乐观态度。Celldex 领导者认为，这一消息表明 CDX-0159 更有可能帮助其他相关疾病的患者，他希望该治疗的适应症能够随着时间的推移而扩大。</blockquote></p><p> Celldex shares have quadrupled in price over the past year as investors have grown more optimistic about the company's monoclonal antibody biotechnology. If it can keep generating positive trial results, then Celldex could have a lot further to rise in the months and years ahead.</p><p><blockquote>随着投资者对该公司的单克隆抗体生物技术更加乐观，Celldex 的股价在过去一年中翻了两番。如果它能够继续产生积极的试验结果，那么Celldex可能会在未来几个月和几年内进一步上升。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>You Should Know About Monday's 2 Big Nasdaq Winners<blockquote>你应该知道周一纳斯达克的两大赢家</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYou Should Know About Monday's 2 Big Nasdaq Winners<blockquote>你应该知道周一纳斯达克的两大赢家</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-07-13 08:27</span>\n</p>\n</h4>\n</header>\n<article>\n<p> One's a well-known name, while the other has plenty of potential. <b>Key Points</b></p><p><blockquote>一个是家喻户晓的名字，而另一个有很大的潜力。<b>要点</b></blockquote></p><p> <ul> <li>Markets were generally higher on Monday.</li> <li>One stock rose on news about technological advances with its key products.</li> <li>Another stock released favorable study results in a clinical trial.</li> </ul> The Possible Demise of the iPhone</p><p><blockquote><ul><li>周一市场普遍走高。</li><li>一只股票因其关键产品技术进步的消息而上涨。</li><li>另一只股票在临床试验中发布了有利的研究结果。</li></ul>iPhone可能消亡</blockquote></p><p> Stocks were largely higher on Monday after overcoming a slow start to the trading week. By 2:30 p.m. EDT, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)had climbed about 0.2%, with aspirations to finish at an all-time high.</p><p><blockquote>在克服了交易周开局缓慢的局面后，周一股市大幅走高。到下午 2:30美国东部时间，<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）上涨约 0.2%，有望创下历史新高。</blockquote></p><p> A couple of stocks contributed significantly to the positive mood on Wall Street.<b>Tesla</b>(NASDAQ:TSLA)is a perennial favorite among many investors, and its stock was among the best performers in the mega-cap arena. Meanwhile, tiny<b>Celldex Therapeutics</b>(NASDAQ:CLDX)enjoyed much larger gains that stemmed from good news about one of its candidate treatments. Below, we'll go into more detail about today's moves.</p><p><blockquote>几只股票对华尔街的积极情绪做出了重大贡献。<b>特斯拉</b>（纳斯达克股票代码：TSLA）一直是许多投资者的最爱，其股票是大型股领域表现最好的股票之一。同时，小小的<b>Celldex 治疗</b>（纳斯达克股票代码：CLDX）由于其候选疗法之一的好消息而获得了更大的涨幅。下面，我们将更详细地介绍今天的走势。</blockquote></p><p> <b>Tesla gears up</b></p><p><blockquote><b>特斯拉加快步伐</b></blockquote></p><p> Shares of Tesla were higher by 4%. The stock overcame negative comments from one set of Wall Street analysts even as CEO Elon Musk gave testimony about Tesla's purchase of its SolarCity unit from several years back.</p><p><blockquote>特斯拉股价上涨 4%。尽管首席执行官埃隆·马斯克 (Elon Musk) 就特斯拉几年前收购其 SolarCity 部门一事作证，但该股克服了一组华尔街分析师的负面评论。</blockquote></p><p> One explanation for the optimism about the stock relates to Tesla's self-driving vehicle technology. The company started to enable vehicles whose owners paid in advance for incremental software updates toupgrade to the latest beta version of Tesla's autonomous driving software. Yet Tesla warned drivers not to assume too much about the driver assistance system, in an effort to avoid some of the accidents that have resulted from Tesla owners counting on their vehicles to do too much without any human intervention.</p><p><blockquote>对该股持乐观态度的一个解释与特斯拉的自动驾驶汽车技术有关。该公司开始让车主提前支付增量软件更新费用的车辆升级到特斯拉自动驾驶软件的最新测试版。然而，特斯拉警告司机不要对驾驶员辅助系统假设太多，以避免一些事故，这些事故是由于特斯拉车主在没有任何人工干预的情况下指望他们的车辆做得太多而导致的。</blockquote></p><p> Yet analysts at Citi were skeptical about the release, arguing that early indications suggest minimal improvement in features. Citi is among the most bearish analysts on Tesla, with a sell rating and a price target of $175 per share.</p><p><blockquote>然而，花旗分析师对此次发布持怀疑态度，认为早期迹象表明功能改进甚微。花旗是特斯拉最悲观的分析师之一，给予卖出评级，目标价为每股 175 美元。</blockquote></p><p> Meanwhile, many shareholders are watching Musk's testimony in Delaware court, in which he's been asked to defend his role in Tesla's SolarCity acquisition. Naysayers have centered on family relationships between top-level executives at both companies. Cross-examination, however, got heated and seemingly personal.</p><p><blockquote>与此同时，许多股东正在关注马斯克在特拉华州法院的证词，他被要求为自己在特斯拉收购 SolarCity 中的角色进行辩护。反对者集中在两家公司高层管理人员之间的家庭关系上。然而，交叉询问变得激烈，似乎是针对个人的。</blockquote></p><p> Tesla's ability to move higher shows that shareholders are able to separate Musk's role from the future success of the company. That's a positive development and could support future gains for theelectric car stock.</p><p><blockquote>特斯拉走高的能力表明，股东能够将马斯克的角色与公司未来的成功分开。这是一个积极的发展，可能会支持电动汽车股票未来的上涨。</blockquote></p><p> <b>Celldex gets a win</b></p><p><blockquote><b>Celldex 获胜</b></blockquote></p><p> Elsewhere, shares of Celldex Therapeutics moved higher by 23%. The little-known biotech got an early win with a key candidate treatment in its development pipeline.</p><p><blockquote>在其他地方，Celldex Therapeutics 的股价上涨了 23%。这家鲜为人知的生物技术公司凭借其开发管道中的关键候选疗法取得了早期胜利。</blockquote></p><p> Celldex released positive data late Fridayon its CDX-0159 candidate treatment, which aims to help patients who are dealing with chronic urticaria, another name for hives. The phase 1b study involved 19 patients, and all but one of them had a complete response that included depletion of skin mast cells.</p><p><blockquote>Celldex 周五晚些时候发布了其 CDX-0159 候选疗法的积极数据，该疗法旨在帮助患有慢性荨麻疹（荨麻疹的另一个名称）的患者。1b期研究涉及19名患者，除一名患者外，其余患者均有完全缓解，包括皮肤肥大细胞耗竭。</blockquote></p><p> Obviously, it's still early in the clinical trial process, but CEO Anthony Marucci was still optimistic about the results. The Celldex leader believes that the news points to a higher probability that CDX-0159 could help patients with other related diseases as well, and he's hopeful that the treatment's indications will expand over time.</p><p><blockquote>显然，目前还处于临床试验过程的早期阶段，但CEO安东尼·马鲁奇（Anthony Marucci）仍然对结果持乐观态度。Celldex 领导者认为，这一消息表明 CDX-0159 更有可能帮助其他相关疾病的患者，他希望该治疗的适应症能够随着时间的推移而扩大。</blockquote></p><p> Celldex shares have quadrupled in price over the past year as investors have grown more optimistic about the company's monoclonal antibody biotechnology. If it can keep generating positive trial results, then Celldex could have a lot further to rise in the months and years ahead.</p><p><blockquote>随着投资者对该公司的单克隆抗体生物技术更加乐观，Celldex 的股价在过去一年中翻了两番。如果它能够继续产生积极的试验结果，那么Celldex可能会在未来几个月和几年内进一步上升。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/07/12/you-should-know-about-mondays-2-big-nasdaq-winners/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","CLDX":"塞德斯医疗"},"source_url":"https://www.fool.com/investing/2021/07/12/you-should-know-about-mondays-2-big-nasdaq-winners/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198299202","content_text":"One's a well-known name, while the other has plenty of potential.\n\nKey Points\n\nMarkets were generally higher on Monday.\nOne stock rose on news about technological advances with its key products.\nAnother stock released favorable study results in a clinical trial.\n\nThe Possible Demise of the iPhone\n\nStocks were largely higher on Monday after overcoming a slow start to the trading week. By 2:30 p.m. EDT, theNasdaq Composite(NASDAQINDEX:^IXIC)had climbed about 0.2%, with aspirations to finish at an all-time high.\nA couple of stocks contributed significantly to the positive mood on Wall Street.Tesla(NASDAQ:TSLA)is a perennial favorite among many investors, and its stock was among the best performers in the mega-cap arena. Meanwhile, tinyCelldex Therapeutics(NASDAQ:CLDX)enjoyed much larger gains that stemmed from good news about one of its candidate treatments. Below, we'll go into more detail about today's moves.\nTesla gears up\nShares of Tesla were higher by 4%. The stock overcame negative comments from one set of Wall Street analysts even as CEO Elon Musk gave testimony about Tesla's purchase of its SolarCity unit from several years back.\nOne explanation for the optimism about the stock relates to Tesla's self-driving vehicle technology. The company started to enable vehicles whose owners paid in advance for incremental software updates toupgrade to the latest beta version of Tesla's autonomous driving software. Yet Tesla warned drivers not to assume too much about the driver assistance system, in an effort to avoid some of the accidents that have resulted from Tesla owners counting on their vehicles to do too much without any human intervention.\nYet analysts at Citi were skeptical about the release, arguing that early indications suggest minimal improvement in features. Citi is among the most bearish analysts on Tesla, with a sell rating and a price target of $175 per share.\nMeanwhile, many shareholders are watching Musk's testimony in Delaware court, in which he's been asked to defend his role in Tesla's SolarCity acquisition. Naysayers have centered on family relationships between top-level executives at both companies. Cross-examination, however, got heated and seemingly personal.\nTesla's ability to move higher shows that shareholders are able to separate Musk's role from the future success of the company. That's a positive development and could support future gains for theelectric car stock.\nCelldex gets a win\nElsewhere, shares of Celldex Therapeutics moved higher by 23%. The little-known biotech got an early win with a key candidate treatment in its development pipeline.\nCelldex released positive data late Fridayon its CDX-0159 candidate treatment, which aims to help patients who are dealing with chronic urticaria, another name for hives. The phase 1b study involved 19 patients, and all but one of them had a complete response that included depletion of skin mast cells.\nObviously, it's still early in the clinical trial process, but CEO Anthony Marucci was still optimistic about the results. The Celldex leader believes that the news points to a higher probability that CDX-0159 could help patients with other related diseases as well, and he's hopeful that the treatment's indications will expand over time.\nCelldex shares have quadrupled in price over the past year as investors have grown more optimistic about the company's monoclonal antibody biotechnology. If it can keep generating positive trial results, then Celldex could have a lot further to rise in the months and years ahead.","news_type":1,"symbols_score_info":{"CLDX":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":421,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/142183539"}
精彩评论